Freeline Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of Freeline Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 29,800 shares of FRLN short.

Freeline Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 29,800 shares, an increase of 1.0% from the previous total of 29,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Freeline Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Freeline Therapeutics: Atara Biotherapeutics, Inc. (0.00%), Alector, Inc. (10.91%), Translate Bio, Inc. (0.00%), Curis, Inc. (0.00%), Forma Therapeutics Holdings, Inc. (9.85%), Coherus BioSciences, Inc. (19.69%), Cortexyme, Inc. (26.33%), Vaxcyte, Inc. (13.33%), Scholar Rock Holding Co. (8.09%), and Black Diamond Therapeutics, Inc. (17.30%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling FRLN is an investing strategy that aims to generate trading profit from Freeline Therapeutics as its price is falling. Freeline Therapeutics' stock is trading down $0.24 today. To short Freeline Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Freeline Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Freeline Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FRLN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FRLN, twice per month. The most recent reporting period available is April, 15 2021.